NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
CPH · NOVO-B.CO · DKK
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 03:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · DKK. Historical prices are not a forecast.
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 36.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Novo Nordisk A/S’s forward annual dividend is DKK 7.50 per share, paid semi-annual. The forward yield is 2.88% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Novo Nordisk A/S’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of DKK 4.75. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Novo Nordisk A/S’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Latest available per-share figures in DKK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 7, 2025 | DKK 6.53+11.05% vs estimate | DKK 78.09B+0.19% vs estimate |
|---|
| Q4 2024 | Feb 5, 2025 | DKK 6.35+3.08% vs estimate | DKK 85.80B+7.07% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | DKK 6.12+1.66% vs estimate | DKK 74.08B+2.71% vs estimate |
|---|
THE ANALYST VIEW
25 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
CHF 132.30+CHF 3.08 (+2.38%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 1.53% below the high.
£130.52+£2.88 (+2.26%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 17.04% below the high.
$460.73+$8.90 (+1.97%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
$29.95+$0.50 (+1.7%)
Pfizer Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
